Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.56 |
| ▸ | LCK | P06239 | 6/20 | 0.46 |
| ▸ | ITK | Q08881 | 6/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | PI4KA | P42356 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.44 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.43 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18987364 | 0.91 | USP30 (0.65) | USP30LCKITKROCK2PIK3CA | |
| SCHEMBL13457222 | 0.77 | LCK (0.62) | USP30LCKITKMAP4K1 | |
| SCHEMBL19017747 | 0.75 | USP30 (0.77) | USP30LCKITKROCK2PIK3CA | |
| SCHEMBL18987182 | 0.74 | USP30 (0.65) | USP30LCKITKROCK2PIK3CA | |
| SCHEMBL1463202 | 0.74 | USP30 (0.59) | USP30 | |
| SCHEMBL24977487 | 0.74 | USP30 (0.72) | USP30LCKITKROCK2PIK3CA | |
| SCHEMBL18987081 | 0.72 | USP30 (1.00) | USP30OTUD7BPCSK9 | |
| Trifluoroacetic Acid SCHEMBL29908119 | 0.71 | USP30 (0.49) | USP30 | |
| SCHEMBL15673229 | 0.69 | PIK3CD (0.44) | USP30LCKITKROCK2OTUD7B | |
| SCHEMBL29470534 | 0.69 | PIK3CD (0.44) | USP30LCKITKROCK2OTUD7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958833-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-04-16 | — | — | US | disclosed |
| EP-4122929-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2023-01-25 | — | — | EP | disclosed |
| EP-3390391-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2022-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958833-B2 | Compounds | USP30, USP20, USP10 | USP30 1/4885LCK 3694/4885ITK 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.